Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
| Sponsored by: | MolMed S.p.A. |
| Information provided: | MolMed S.p.A. |
| ClinicalTrials.gov Identifier: | NCT00484276 |
Purpose:
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent. Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria.
| Condition | Intervention | Phase |
|
Malignant Pleural Mesothelioma |
Drug: NGR-hTNF |
Phase 2 |
Eligibility
Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Official Title: NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen
Enrollment Size: Both
Gender: 18 Years
Min. Age: N/A
Max. Age: No
Location and Contact Information
, Milan
Istituto Clinico Humanitas, Rozzano, Milan, Italy,
Status:
, Italy
Istituto Europeo Oncologico, Milan, Italy, ,
Status:
, Italy
Istituto Nazionale dei Tumori, Milan, Italy, ,
Status:
, Italy
Fondazione San Raffaele del Monte Tabor, Milan, Italy, ,
Status:
Last modified: July 29 2010.
